Analysts at Royal Bank Of Canada initiated coverage on shares of Eupraxia Pharmaceuticals (TSE:EPR – Get Free Report) in a note issued to investors on Monday, Zacks reports. The firm set a “moderate buy” rating on the stock.
Separately, Wedbush upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Strong Buy”.
Get Our Latest Stock Report on EPR
Eupraxia Pharmaceuticals Price Performance
Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biotechnology company developing locally acting therapies designed to improve the delivery, duration and tolerability of established medicines. The company’s platform, DiffuSphere, uses biodegradable polymeric microspheres to provide controlled and sustained drug release at targeted sites in the body.
Eupraxia’s lead programs include EP-104IAR, an extended-release intra-articular formulation intended to provide longer-lasting relief for people with knee osteoarthritis, and EP-104GI, an orally administered formulation being developed for gastrointestinal diseases, including eosinophilic esophagitis.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
